Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment

ConferenceKisunlaP-tau217 blood testPositive

AI Analysis

Summary

Lilly will present research on Alzheimer's disease diagnostics and therapeutics at AAIC 2026, including new data on P-tau217 blood tests and long-term extension analyses of Kisunla (donanemab-azbt) comparing diagnostic performance with amyloid PET imaging.

Importance:4/10

Sentiment:

0.30

Alzheimer's diseasediagnostic biomarkeramyloid-targeting therapyblood testlong-term extension dataAAIC 2026

Related Companies

$LLY

Read the original article

Published by PR Newswire Biotech on July 9, 2026 11:30 AM

Read Original